Kairos Pharma, LTD. (KAPA)
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016. The company's operations are headquartered in Los Angeles, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Kairos Pharma, Ltd.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 3.39M shares outstanding
USKairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer.
Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016.
The company's operations are headquartered in Los Angeles, California.
Leadership
John S. Yu
Chief Executive Officer, Chairman & Secretary
Neil A. Bhowmick
Chief Scientific Officer
Ramachandran Murali
Vice President of Research & Development
Douglas W. Samuelson
Chief Financial Officer
Employees
4
Country
US
Sector
Healthcare
Website
kairospharma.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Yu John S | CEO and Chairman | Grant/Award | 190.8K | -- | Oct 8, 2025 |
 Singhvi Rahul | Director | Grant/Award | 19.1K | -- | Oct 8, 2025 |
 Bhowmick Neil | Chief Scientific Officer | Grant/Award | 171.8K | -- | Oct 8, 2025 |
 Bae Hyun W. | Director | Grant/Award | 19.1K | -- | Oct 8, 2025 |
 Murali Ramachandran | VP of Research and Development | Grant/Award | 152.7K | -- | Oct 8, 2025 |
 Samuelson Doug | Chief Financial Officer | Grant/Award | 152.7K | -- | Oct 8, 2025 |
| Name | Shares | % | Source |
|---|---|---|---|
 Bhowmick Neil Chief Scientific Officer | 187.4K | 5.5% | FORM 4 |
Armistice Capital, LLC · may incl. warrants· filed Aug 2025 | 126.4K | 3.7% | 13G |
CITADEL ADVISORS LLC | 44.3K | 1.3% | 13F |
 Murali Ramachandran VP of Research and Development | 42.8K | 1.3% | FORM 4 |
 Samuelson Doug Chief Financial Officer | 41.9K | 1.2% | FORM 4 |
VANGUARD CAPITAL MANAGEMENT LLC | 33.1K | 1.0% | 13F |
 Yu John S CEO and Chairman, Director, 10% Owner | 32.9K | 1.0% | FORM 4 |
Virtu Financial LLC | 11.7K | 0.3% | 13F |
GEODE CAPITAL MANAGEMENT, LLC | 11.3K | 0.3% | 13F |
 Bae Hyun W. Director | 10.5K | 0.3% | FORM 4 |
Insiders
- Yu John SCEO and Chairman
- Singhvi RahulDirector
- Bhowmick NeilChief Scientific Officer
- Bae Hyun W.Director
- Murali RamachandranVP of Research and Development
- Samuelson DougChief Financial Officer
- Keyoung Hansoo MichaelDirector
based on 3.39M shares outstanding
US30d Avg
983.33K
60d Avg
542.32K
90d Avg
385.70K